Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer.

MLA

Bahman, Fatemah, et al. “Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer.” Journal of Personalized Medicine, vol. 11, no. 6, June 2021. EBSCOhost, https://doi.org/10.3390/jpm11060559.

APA

Bahman, F., Pittalà, V., Haider, M., & Greish, K. (2021). Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer. Journal of Personalized Medicine, 11(6). https://doi.org/10.3390/jpm11060559

Chicago

Bahman, Fatemah, Valeria Pittalà, Mohamed Haider, and Khaled Greish. 2021. “Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer.” Journal of Personalized Medicine 11 (6). doi:10.3390/jpm11060559.